Dr. Clay Siegall is a scientist and co-founded Seattle Genetics in 1998. Since then he has dedicated his life to the pursuit of genetic research and finding cures for disease such as cancer. Dr. Siegall received a Ph.D. in Genetics from George Washington
University and a B.S. in Zoology from the University of Maryland. As a scientist Clay has built up his company on the integrity of scientific principles and is committed to solid research in the modern era. Moreover, in line with his love of scientific research, Seattle Genetics offers grants to fund cancer research through the program which is known as the Independent Medical Education and Charitable Grants. In addition to his work with Seattle Genetics, he was recently made a board member of Mirna Therapeutics Inc and is also a member of the board of directors for Ultragenyx a pharmaceutical company. Dr Siegall has a net worth estimated to be $9,559,397.
In a recent article for the Seattle business mag, Seattle Genetics CEO Dr Clay Siegall was interviewed. The focus of the article was to highlight the growth of this pharma giant and to highlight the exceptional work they are doing in the fight against illness. Furthermore, seattle genetics is focused on breaking into the bigger, international pharmaceutical market and they are so determined to cure diseases like Hodgkin’s Lymphoma that they sold international commercial right to Takeda Oncology in a bid to raise capital for research into Adcetris (the company’s flagship drug). Growth of the company has not subsided with sales increasing by 45% since 2014. The total sales for 2016 were about $418 million. The company is working on 11 other drugs as yet unnamed in the hopes of fighting other types of cancer, and despite the political and economic climate stability he and his company will never give up the fight against cancer.
One of the worst diseases in the world that takes millions of lives each year is Cancer, and while there are numerous studies and research being conducted worldwide on it, the cure is yet to be found. Many different types of cancers are curable now, but one of the things that are missing in most of the studies and research is the availability of data.Eric Lefkofsky, widely known for his first startup Groupon that is worth close to $3 Billion today, has recently co-founded a medical research firm named Tempus. The creation of Tempus aims at building co-relating data that would help the physicians and researchers across the globe to get the data they need in their study to develop effective cancer therapies. Tempus aims at gathering clinical, molecular as well as patient outcome data from various medical research centers and facilities to make it available for the medical professionals so that they can provide better and more personalized treatment to the patients.
The idea of creating Tempus came to Eric Lefkofsky when his wife Liz Lefkofsky was diagnosed with breast cancer, and he realized that the cancer-related databases are not optimally organized or structured. He said data as to how much a particular cancer medicine was used in the past six months and what the result was after using can take months to gather manually. However, if such data is available easily with a click of a button to the physicians, oncologists, and researchers, the research conducted as well as the treatment provided can be far more efficient. It can save time as well as millions of dollars that are being fuelled into cancer research each year.
Eric Lefkofsky is one of the most successful entrepreneurs in the United States today and has co-founded many other firms other than Groupon and Tempus, which includes MediaOcean, Uptake Technologies, Lightbank, Echo Global Logistics, and InnerWorkings. Eric Lefkofsky is also a generous philanthropist and donates to various charities across the country through Lefkofsky Family Foundation, which works actively to help empower local communities through providing better education, social support, and healthcare. He has also written a book named Accelerated Disruption.
Tempus is a data analytics company that was founded by Eric Lefkofsky. The company has software and computers that can store, process and sift through large amounts of data to find patterns. Recently, Tempus has begun a partnership with the University of Chicago to help better treat cases of breast cancer.Tempus’ capabilities include being able to do genomic sequencing for patients who are receiving treatment at the University of Chicago for breast cancer. In addition the company utilizes machine learning technology to build upon previous data from both past and existing patients. Genomic sequencing when combined with machine learning give cancer researchers and physicians a vast swathe of data that can better predict how a person will respond to a certain treatment option for cancer and how likely that treatment will be successful.
Doctors at the University of Chicago say that there is a large amount of information out there on cancer patients. They also say that there is lack of storage, analysis and sharing of data when it comes to past cancer patients. Tempus is changing this by storing data and allowing it to be shared and analyzed. The hope is that Tempus can help customize medicine and create an effective individually customized cancer solution for every patient that will be most effective for them.
Eric Lefkofsky is also the founder of Groupon. This is a popular online marketing company. Its business model involves working with businesses to offer customers large discounts or sales on products and services. In exchange for offering these large discounts or sales, the business or corporation is given access to a large customer base that is willing to try out the new product or service at the discounted value. Businesses get access to a large customer base, while customers get discounts and special offers through Groupon.Mr. Lefkofsky also has an investment venture that is called Lightbank. This venture invests money in startups that have the potential to impact society or develop into big companies. Both Lightbank, Tempus and Groupon are based in the windy city of Chicago at 600 West Chicago Avenue along the banks of the Chicago River.
Mikhail Blagosklonny is a world-famous oncologist, author, and editor. He has made notable contributions to the overall field of medicine. He currently teaches oncology at Buffalo University’s Roswell Park Cancer Institute, where he is also a board member. Prof. Mikhail earned his M.D and PhD in internal and experimental medicine and cardiology at St. Petersburg’s First Pavlov State Medical University. This heralded the beginning of a highly successful career, which has seen him serve at senior positions in notable institutions such as the Ordway Research Institute and the New York Medical College.
Mikhail’s Research on Aging and Rapamycin
Prof. Mikhail Blagosklonny has led numerous high-profile research teams, which have successfully carried out studies pertaining to the human aging process. At a personal level, he has formulated a premise about the role played by TOR signaling in cancer and aging. This has led him to propose the use of rapamycin, which is a renowned cancer treatment, to slow down the aging process. Mikhail’s hypothesis has been well received within the medical fraternity. He is regarded as one of the most passionate proponents of rapamycin in longevity studies. This has boosted his profile within the fraternity.
Prof. Mikhail Blagoskloony is best known for being the brains behind Oncotarget, which is a pioneer peer review publication that highlights issues related to oncology research. Oncotarget prides itself in being the most up-to-date open access journal within the medical field, which covers research on aspects related to oncology. Its publisher is Impact Journals. Mikhail established the journal in 2010 and serves as its editor-in-chief alongside Andrei V. Gudkov. The journal is indexed and abstracted in Scopus, the Science Citation Index Expanded, and BIOSIS Previews. This proves its prominence within the medical field.
Other Editorial Ventures
Besides Oncotarget, Prof. Mikhail is the editor-in-chief of Aging. This is a monthly medical journal that covers the molecular mechanics of the aging process, gerontology, and senescence. He similarly serves in the same position at Cell Death & Differentiation, which is another notable peer reviewed journal. Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249451/
Blagosklonny’s Career Highlights
Mikhail has distinguished himself as a dedicated scientist, more so in the area of aging and cancer research. Mikhail Blagosklonny’s works have been cited by major publications across the world. His breakthrough discoveries have similarly helped to shed light on medical issues that were previously seen to be obscure. Mikhail has been described as a preeminent researcher with a unique understanding of cancer biology and therapy by his peers. His hyper-functionary theory of aging has equally been well received and applauded by peers.
Read works by Mikhail Blagosklonny on Google Scholar